Revelation Biosciences (NASDAQ:REVB) Shares Down 6.7%

Revelation Biosciences, Inc. (NASDAQ:REVB)’s stock price fell 6.7% during mid-day trading on Wednesday . The company traded as low as $0.94 and last traded at $0.99. 343,654 shares traded hands during trading, a decline of 93% from the average session volume of 4,836,348 shares. The stock had previously closed at $1.06.

Revelation Biosciences Stock Down 6.7 %

The firm has a market capitalization of $1.62 million, a P/E ratio of -0.03 and a beta of 0.19. The company has a fifty day simple moving average of $1.43 and a 200 day simple moving average of $2.06.

Revelation Biosciences (NASDAQ:REVB) last posted its quarterly earnings results on Friday, August 9th. The company reported ($1.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.81) by $0.27. As a group, equities analysts expect that Revelation Biosciences, Inc. will post -12.46 earnings per share for the current fiscal year.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.